Endocrine Journal 2012-01-01

Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism.

Alessandro Mussa, Roberta Camilla, Silvia Monticone, Francesco Porta, Daniele Tessaris, Francesca Verna, Paolo Mulatero, Silvia Einaudi

Index: Endocr. J. 59(6) , 497-502, (2012)

Full Text: HTML

Abstract

Familial hyperaldosteronism (FH) encompasses 3 types of autosomal dominant hyperaldosteronisms leading to inheritable hypertension. FH type II (FH-II), undistinguishable from sporadic hyperaldosteronism, represents the most frequent cause of inheritable hypertension and is believed to only manifest in adults. FH-III is a severe variety of PA resistant to pharmacotherapy and recently demonstrated to be caused by mutations in the gene encoding the potassium channel KCNJ5. In this report, we describe a FH pediatric patient, remarkable both for age at onset and unusual presentation: a two-years old girl with polyuric-polydipsic syndrome and severe hypertension, successfully treated with canrenone and amiloride. The girl had severe hypertension, hypokalemia, hypercalciuria, suppressed renin activity, high aldosterone, and unremarkable adrenal imaging. FH type I was ruled out by glucocorticoid suppression test, PCR test for CYP11B1/CYP11B2 gene, and urinary 18-oxo-cortisol and 18-hydroxy-cortisol excretion, which was in FH-II range. In spite of a clear-cut FH-II phenotype, the girl and her mother were found to harbor a FH-III genotype with KCNJ5 mutation (c.452G>A). Treatment with canrenone was started, resulting in prompt normalization of electrolytes and remission of polyuric-polydypsic syndrome. The addition of amiloride led to a complete normalization of blood pressure. This report expands the phenotypic spectrum of FH-III to a milder end, mimiking FH-II phenotype demonstrating that pharmacotherapy may be effective. This also implies that FH-II/III should be considered in the differential diagnosis of hypertensive children and, perhaps, that the offspring of patients with hyperaldosteronism should be screened for hypertension.


Related Compounds

  • Canrenone

Related Articles:

Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.

2014-05-01

[Expert Opin. Pharmacother. 15(7) , 909-12, (2014)]

Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.

2013-05-01

[Br. J. Clin. Pharmacol. 75(5) , 1202-12, (2013)]

The effects of canrenone on inflammatory markers in patients with metabolic syndrome.

2015-02-01

[Ann. Med. 47(1) , 47-52, (2015)]

Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.

2012-11-01

[Br. J. Clin. Pharmacol. 74(5) , 864-72, (2012)]

Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.

2008-12-01

[Ther. Drug Monit. 30(6) , 744-7, (2008)]

More Articles...